Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

Abstract Background Plasmablasts and plasma cells play a key role in many autoimmune diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). This study was undertaken to evaluate the potential of targeting CD38 as a plasma cell/plasmablast depletion mechanism by daratumum...

Full description

Bibliographic Details
Main Authors: Suzanne Cole, Alice Walsh, Xuefeng Yin, Mihir D. Wechalekar, Malcolm D. Smith, Susanna M. Proudman, Douglas J. Veale, Ursula Fearon, Costantino Pitzalis, Frances Humby, Michele Bombardieri, Amy Axel, Homer Adams, Christopher Chiu, Michael Sharp, John Alvarez, Ian Anderson, Loui Madakamutil, Sunil Nagpal, Yanxia Guo
Format: Article
Language:English
Published: BMC 2018-05-01
Series:Arthritis Research & Therapy
Subjects:
CD38
Plasma cell
Daratumumab
Rheumatoid arthritis
Systemic lupus erythematosus
Online Access:http://link.springer.com/article/10.1186/s13075-018-1578-z

Similar Items

Similar Items